Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease.
Daniela PonceMarilia Mastrocolla de Almeida CardosoJuliana Rodrigues Machado RúgoloSilvana Andrea Molina LimaLuís Gustavo Modelli de AndradeDaniel da Silva Pereira CuradoPublished in: Jornal brasileiro de nefrologia (2023)
Cinacalcet was dominant to avoid parathyroidectomies, being cost-effective.